MX2017013501A - Inhibidor de bromodominio. - Google Patents
Inhibidor de bromodominio.Info
- Publication number
- MX2017013501A MX2017013501A MX2017013501A MX2017013501A MX2017013501A MX 2017013501 A MX2017013501 A MX 2017013501A MX 2017013501 A MX2017013501 A MX 2017013501A MX 2017013501 A MX2017013501 A MX 2017013501A MX 2017013501 A MX2017013501 A MX 2017013501A
- Authority
- MX
- Mexico
- Prior art keywords
- cyclopropylmethoxy
- methylisoquinolin
- pharmaceutical compositions
- bromodomain
- inhibitor
- Prior art date
Links
- 229940125763 bromodomain inhibitor Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 5
- -1 cyclopropylmethoxy Chemical group 0.000 abstract 3
- 229920000642 polymer Polymers 0.000 abstract 3
- UWZAJPITKGWMFJ-UHFFFAOYSA-N 4-[2-(cyclopropylmethoxy)-5-methylsulfonylphenyl]-2-methylisoquinolin-1-one Chemical compound Cn1cc(-c2cc(ccc2OCC2CC2)S(C)(=O)=O)c2ccccc2c1=O UWZAJPITKGWMFJ-UHFFFAOYSA-N 0.000 abstract 1
- 102000001805 Bromodomains Human genes 0.000 abstract 1
- 108050009021 Bromodomains Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000010922 spray-dried dispersion Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Se describe en la presente solicitud el inhibidor de bromodominio 4-[2- (ciclopropilmetoxi)-5-metilsulfonilfeni1]-2-metilisoquinolin -1-ona, que incluye sus formas cristalinas, formas amorfas, solvatos e hidratos, al igual que composiciones farmacéuticas que incluyen este inhibidor de bromodominio. En algunas formas de realización, la composición farmacéutica comprende 4--[2-(ciclopropilmetoxi)-5- metilsulfonilfeni1]-2-metilisoquinoli n-1-ona que ha sido procesada por medio de la micronización o la dispersión secada por pulverización. En algunas formas de realización, la composición farmacéutica además comprende por lo menos un polímero. En algunas formas de realización, las composiciones farmacéuticas comprenden una matriz de polimero sólida que comprende 4-(2- (ciclopropilmetoxi)-5-metilsulfonilfeni 11-2-metilisoquinolin-1-ona y por lo menos un polímero. Las composiciones farmacéuticas que comprenden 4-[2- (ciclopropilmetoxi)-5-metilsulfonilfenil]-2-metilisoquinolin-1-on a son útiles para el tratamiento de cáncer o enfermedad neoplásica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562151205P | 2015-04-22 | 2015-04-22 | |
| PCT/US2016/029029 WO2016172618A1 (en) | 2015-04-22 | 2016-04-22 | Bromodomain inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017013501A true MX2017013501A (es) | 2018-02-09 |
| MX377159B MX377159B (es) | 2025-03-07 |
Family
ID=57143581
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020010899A MX390077B (es) | 2015-04-22 | 2016-04-22 | Inhibidor de bromodominio. |
| MX2017013501A MX377159B (es) | 2015-04-22 | 2016-04-22 | Inhibidor de bromodominio. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020010899A MX390077B (es) | 2015-04-22 | 2016-04-22 | Inhibidor de bromodominio. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20160310423A1 (es) |
| EP (1) | EP3285770A4 (es) |
| JP (1) | JP2018513863A (es) |
| KR (1) | KR20170139119A (es) |
| CN (1) | CN107613981A (es) |
| AR (1) | AR104340A1 (es) |
| AU (1) | AU2016252992A1 (es) |
| BR (1) | BR112017022691A2 (es) |
| CA (1) | CA2983446C (es) |
| CL (1) | CL2017002679A1 (es) |
| CO (1) | CO2017011482A2 (es) |
| EA (1) | EA201792317A1 (es) |
| EC (1) | ECSP17071545A (es) |
| HK (1) | HK1243948A1 (es) |
| IL (1) | IL255120B (es) |
| MX (2) | MX390077B (es) |
| PE (1) | PE20180036A1 (es) |
| PH (1) | PH12017501933A1 (es) |
| SG (1) | SG11201708627TA (es) |
| TW (1) | TW201642860A (es) |
| WO (1) | WO2016172618A1 (es) |
| ZA (1) | ZA201707186B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR104259A1 (es) * | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
| US10702517B2 (en) | 2015-04-22 | 2020-07-07 | Celgene Quanticel Research, Inc. | Bromodomain inhibitor |
| GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| EP3528810A4 (en) * | 2016-10-20 | 2020-06-17 | Celgene Quanticel Research, Inc. | BROMDOMAIN INHIBITOR |
| EP3532059B1 (en) | 2016-10-27 | 2022-01-26 | Celgene Quanticel Research, Inc. | Bromodomain and extra-terminal protein inhibitor combination therapy |
| US11566004B2 (en) * | 2018-07-23 | 2023-01-31 | Celgene Quanticel Research, Inc. | Process for the preparation of bromodomain inhibitor |
| EP4294397A1 (en) * | 2021-02-22 | 2023-12-27 | Celgene Quanticel Research, Inc. | Bromodomain (bet) inhibitor for use in treating prostate cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0420722D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| GB0919434D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| WO2013097052A1 (en) * | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| EP3640241B1 (en) * | 2013-10-18 | 2022-09-28 | Celgene Quanticel Research, Inc. | Bromodomain inhibitors |
| EP3528810A4 (en) * | 2016-10-20 | 2020-06-17 | Celgene Quanticel Research, Inc. | BROMDOMAIN INHIBITOR |
-
2016
- 2016-04-19 TW TW105112168A patent/TW201642860A/zh unknown
- 2016-04-21 AR ARP160101100A patent/AR104340A1/es unknown
- 2016-04-22 SG SG11201708627TA patent/SG11201708627TA/en unknown
- 2016-04-22 WO PCT/US2016/029029 patent/WO2016172618A1/en not_active Ceased
- 2016-04-22 HK HK18103550.6A patent/HK1243948A1/zh unknown
- 2016-04-22 PE PE2017002306A patent/PE20180036A1/es not_active Application Discontinuation
- 2016-04-22 AU AU2016252992A patent/AU2016252992A1/en not_active Abandoned
- 2016-04-22 KR KR1020177033575A patent/KR20170139119A/ko active Pending
- 2016-04-22 EP EP16784024.8A patent/EP3285770A4/en not_active Withdrawn
- 2016-04-22 CA CA2983446A patent/CA2983446C/en active Active
- 2016-04-22 JP JP2017554566A patent/JP2018513863A/ja active Pending
- 2016-04-22 MX MX2020010899A patent/MX390077B/es unknown
- 2016-04-22 EA EA201792317A patent/EA201792317A1/ru unknown
- 2016-04-22 BR BR112017022691-0A patent/BR112017022691A2/pt not_active Application Discontinuation
- 2016-04-22 MX MX2017013501A patent/MX377159B/es active IP Right Grant
- 2016-04-22 CN CN201680032770.1A patent/CN107613981A/zh active Pending
- 2016-04-22 US US15/136,761 patent/US20160310423A1/en not_active Abandoned
-
2017
- 2017-10-18 IL IL255120A patent/IL255120B/en active IP Right Grant
- 2017-10-20 CL CL2017002679A patent/CL2017002679A1/es unknown
- 2017-10-23 ZA ZA2017/07186A patent/ZA201707186B/en unknown
- 2017-10-23 PH PH12017501933A patent/PH12017501933A1/en unknown
- 2017-10-26 EC ECIEPI201771545A patent/ECSP17071545A/es unknown
- 2017-11-08 CO CONC2017/0011482A patent/CO2017011482A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL255120A0 (en) | 2017-12-31 |
| CA2983446A1 (en) | 2016-10-27 |
| KR20170139119A (ko) | 2017-12-18 |
| PE20180036A1 (es) | 2018-01-09 |
| HK1243948A1 (zh) | 2018-07-27 |
| JP2018513863A (ja) | 2018-05-31 |
| TW201642860A (zh) | 2016-12-16 |
| EP3285770A4 (en) | 2018-10-31 |
| AU2016252992A1 (en) | 2017-11-09 |
| ZA201707186B (en) | 2019-01-30 |
| SG11201708627TA (en) | 2017-11-29 |
| US20160310423A1 (en) | 2016-10-27 |
| CO2017011482A2 (es) | 2018-01-31 |
| CL2017002679A1 (es) | 2018-05-25 |
| WO2016172618A1 (en) | 2016-10-27 |
| MX377159B (es) | 2025-03-07 |
| CA2983446C (en) | 2024-04-09 |
| MX390077B (es) | 2025-03-20 |
| EA201792317A1 (ru) | 2018-03-30 |
| ECSP17071545A (es) | 2017-12-01 |
| AR104340A1 (es) | 2017-07-12 |
| BR112017022691A2 (pt) | 2018-07-17 |
| MX2020010899A (es) | 2022-02-15 |
| NZ736630A (en) | 2024-03-22 |
| IL255120B (en) | 2021-03-25 |
| CN107613981A (zh) | 2018-01-19 |
| PH12017501933A1 (en) | 2018-03-19 |
| EP3285770A1 (en) | 2018-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017013501A (es) | Inhibidor de bromodominio. | |
| CL2019001714A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer. | |
| UY37224A (es) | Derivados aromáticos de sulfonamida | |
| MX2021009673A (es) | Moduladores de ror-gamma. | |
| MX382671B (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington | |
| CL2017000902A1 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| UY37098A (es) | Moduladores de ror-gamma | |
| CU20170089A7 (es) | Derivados de quinazolina utilizados para tratar el vih | |
| MX2018000412A (es) | Moduladores de diaciglicerol aciltransferasa 2 (dgat2). | |
| ECSP17026210A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
| CL2016002812A1 (es) | Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación. | |
| CL2016002169A1 (es) | Inhibidores de diacilglicerol aciltransferasa 2 para uso en el tratamiento de trastornos metabólicos y relacionados. | |
| MX2017002954A (es) | Formas solidas cristialinas de 6-carboxi-2-(3,5-diclorofenil)-benz oxazol. | |
| CO2019011546A2 (es) | Compuestos y métodos para el tratamiento de enfermedades parasitarias | |
| CL2017000979A1 (es) | Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina | |
| UY36145A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| AR109859A1 (es) | Inhibidor de bromodominio | |
| MX2017007955A (es) | Formas solidas que comprenden (1e, 4e)-2-amino-n,n-dipropil-8-(4-( pirrolidina-1-carbonil)fenil)-3h-benzo[b]azepina-4-carboxamida, composiciones de las mismas y usos de las mismas. | |
| DOP2018000197A (es) | Compuestos de cinnolin-4-amina y su uso en el tratamiento del cáncer | |
| CL2017002229A1 (es) | Inhibidores de bace1. | |
| BR112018013364A2 (pt) | forma cristalina e composição farmacêutica | |
| CO2020003134A2 (es) | Moduladores de la expresión de enac | |
| CU20150065A7 (es) | Compuestos derivados de bencil 4-((2-(triazol-5-il)acetamido)metil)piperidin-1- carboxilato activos como inhibidores de autotaxina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |